Immune Checkpoint Proteins
We offer an expanding selection of bioactive recombinant immune checkpoint proteins, from leading targets like PD-1, PD-L1 and CTLA-4 to emerging ones such as TIGIT and LAG-3.
Immune Checkpoint Proteins
The immune checkpoint (ICP) molecules refer to ligand-receptor pairs that exert inhibitory or stimulatory effects on immune responses. Most of the ICP proteins that have been described are expressed on cells of the adaptive immune system, particularly on T cells, and of the innate immune system. ICPs act as important immune regulators in maintaining immune homeostasis and preventing autoimmunity.
The immune system plays a key role in the recognition and destruction of cancerous cells. Utilizing and enhancing these properties lies at the heart of immunotherapy. Immune checkpoint therapies that target immuno-suppressive proteins such as PD-1, PD-L1 and CTLA4 have led to transformative new treatments for cancer.
The immune checkpoint (ICP) molecules refer to ligand-receptor pairs that exert inhibitory or stimulatory effects on immune responses.
Chemsis offers a large selection of proteins for studying current and emerging immune checkpoint proteins. Our portfolio includes recombinant proteins for multiple different species that are available either untagged, or with Fc, His, or biotin tags. All of our proteins are rigorously tested for bioactivity and lot-to-lot consistency, and we have scalable production capabilities to be able to deliver the quantities needed for pharmaceutical development and manufacturing.
Popular Immune Checkpoint Proteins
| PD-1 | PD-L1 |
| CTLA-4 | CD28 |
| TIGIT | CD155/PVR |
| SIRP alpha | CD47 |
| 4-1BB | 4-1BB Ligand |
| B7-1 | B7-2 |
| LAG-3 | Galectin-9 |
| CD40 | CD40 Ligand |
| ICOS | VISTA/B7-H5 |
Next Generation Immune Checkpoint Proteins
| Siglecs | VSTMs |
| Butyrophilins | VSIGs |
| CEACAMs | LILRA/B |
